Website
News25/Ratings12
News · 26 weeks63-50%
2025-10-262026-04-19
Mix2190d
- Other10(48%)
- SEC Filings4(19%)
- Analyst2(10%)
- Insider2(10%)
- Earnings2(10%)
- Offering1(5%)
Latest news
25 items- PRVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical
- PRVerastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's CancersPatients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of response with a median follow-up of two years 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type recurrent LGSOC remained on therapy for more than one year After two years of follow-up, the combination therapy continued to demonstrate a well-tolerated safety profile, with no new safety signals and a low discontinuation rate due to adverse events Poster presentation of new exposure response analysis demonstrates that the best therapeutic effect of avutometinib plus defactinib can be achieved when using the approv
- SECSEC Form DEF 14A filed by Verastem Inc.DEF 14A - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The 141,000 restricted stock units granted to the eleven new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee's date of hire, with the remaining shares vesting quarterly over the next three (3)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- INSIDERSEC Form 4 filed by Calkins Daniel4 - Verastem, Inc. (0001526119) (Issuer)
- PRVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In preclinical pancreatic, lung, and colorectal cancer models, VS-7375 (dual ON/OFF inhibitor) showed deeper and more sustained tumor regression compared to ON-only G12D or pan-RAS inhibitors Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held April 17-22, 2026, in San Diego, CA. "Preclin
- PRVerastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's CancersPlenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers. Additional abstracts accepted for presentation will also be shared at the meeting being held on April 10-13, 2026, in San Juan, Puerto Rico. "W
- ANALYSTBTIG Research resumed coverage on Verastem with a new price targetBTIG Research resumed coverage of Verastem with a rating of Buy and set a new price target of $19.00
- SECVerastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 10-K filed by Verastem Inc.10-K - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business UpdatesAVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations Company cash, cash equivalents, and
- PRVerastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's websit
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
- INSIDERPresident and CEO Paterson Dan sold $6,489 worth of shares (970 units at $6.69), decreasing direct ownership by 0.16% to 612,919 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- ANALYSTH.C. Wainwright initiated coverage on Verastem with a new price targetH.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00
- SECVerastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven CancersBased on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251 Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net
- PR$668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsIssued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers where clinical velocity is finally shattering historical benchmarks. With the FDA's 2026 framework explicitly prioritizing accelerated pathways for platforms showing superior objective response rates and durability[2], a select group of innovators is unlocking the immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ:ONCY), Pfizer (NYSE:PFE),
- INSIDERChief Financial Officer Calkins Daniel was granted 16,665 shares, increasing direct ownership by 16% to 121,384 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERPresident and CEO Paterson Dan was granted 213,785 shares, increasing direct ownership by 53% to 613,889 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- INSIDERPresident and CEO Paterson Dan sold $73,898 worth of shares (10,321 units at $7.16), decreasing direct ownership by 3% to 400,104 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)